Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin

Journal of Cutaneous Pathology

Volumn 34, Issue 6, 2007, Pages 474-480

  Ivan, Doina ^a   Nash, Jason W ^a   Prieto, Victor G ^a   Calonje, Eduardo ^b   Lyle, Stephen ^c   Diwan, A Hafeez ^a   Lazar, Alexander J F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P63;

ADENOCARCINOMA; ADNEXA DISEASE; APOCRINE CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; PROTEIN EXPRESSION; SKIN CARCINOMA; SKIN METASTASIS; VISCERA;

ADENOCARCINOMA, MUCINOUS; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASMS, ADNEXAL AND SKIN APPENDAGE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34249106424     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00644.x     Document Type: Article

References (29)

1. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29 encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cells 1998 2:305.
2. Levrero M, De Laurenzi V, Constanzo A, Gong J, Wang JI, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000 113:1661.
3. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996 10:1054.
4. Yang A, McLeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000 3:199.
5. Yang A, Kaghad M, Caput D, McLeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002 18:90.
6. Parsa R, Yang A, McLeon F, Green H. Association of p63 in proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999 113.
7. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 2001 98:3156.
8. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999 398:708.
9. Yang A, Schweitzer R, Sun D. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999 398:714.
10. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002 198:417.
11. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform in head and neck squamous cell carcinoma. Laryngoscope 2004 114:2063.
12. Williams MD, Ohshiro K, Elliott D, Luna MA, El-Naggar AK. Differential role for p63 gene isotypes (delta N and TA) in head and neck squamous tumorigenesis. Abstract presented at the Annual Meeting of the United States and Canadian Academy of Pathology, Atlanta 2006.
13. Celli J, Duijf P, Hamel BC. Heterozygous germ cell mutations in the p53 homolog p63 are the cause of ECC syndrome. Cell 1999 99:143.
14. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in normal and tumor tissues. Clin Cancer Res 2002 8:494.
15. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 4/6 and cytokeratin 14 and 51 in normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003 443:122.
16. Signoretti S, Waltregny D, Dilks J. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000 157:1769.
17. Glickman JN, Yang A, Shahsafei A, McLeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001 32:1157.
18. Barbareschi M, Pecciarini L, Cangi MG. P63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of human breast. Am J Surg Pathol 2002 25:1054.
19. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002 9:280.
20. Reis-Filho, Torio B, Albergaria A, Schmitt FC. P63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002 29:517.
21. Tsujita-Kyutoku M, Kuichi K, Danbara N, Yuri T, Senzaki H, Tsubura A. p63 expression in normal human epidermis and epidermal appendages and their tumors. J Cutan Pathol 2003 30:11.
22. Ivan D, Diwan AH, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to skin. Mod Pathol 2005 18:137.
23. Qureshi HS, Ormsby AH, Lee MW, Zarbo RJ, Ma CK. The diagnostic utility of p63, CK5/6, CK 7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. J Cutan Pathol 2004 31:145.
24. Brownstein MH, Helwig EB. Patterns of cutaneous metastasis. Arch Dermatol 1972 105:862.
25. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993 29:228.
26. Saeed S, Keehn CA, Morgan MB. Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal. J Cutan Pathol 2004 31:419.
27. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981 75:816.
28. Ivan D, Diwan AH, Esteva FJ, Prieto VG. Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions. Mod Pathol 2004 17:811.
29. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001 116:823.